Brazil. Industrial biosciences company Amyris, Inc. announced that it has sold its Brazilian production facilities to Royal DSM. The companies established a long-term manufacturing partnership for Amyris' high-volume products.
The consideration of Amyris Brasil Ltda, which owns and operates the Brotas 1 production facility, and the intellectual property related to Farnesene, a key bio-based intermediary, is US$58 million plus an additional value-sharing agreement over a three-year period amounting to US$37.5 million.
DSM will continue existing supply agreements with Amyris and other parties. DSM will also supply Amyris with specialty compounds until it completes its Brotas 2 specialty production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining manufacturing process development and commercial support capacity located in Campinas, Brazil.
Subject to customary conditions, the transaction is expected to close in the coming months.
The strategic alliance between DSM and Amyris began in May 2017 with a DSM equity investment in Amyris, and has since expanded with several significant product development collaborations.
